Aprea’s mission is to be the leading player in the development and commercialization of p53-targeted cancer therapies.
Aprea Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage reponse (DDR) pathways.
CEO
Oren Gilad, PhD
Sub segment
Pharmaceutical
Location
Massachusetts, USA
